Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 14/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500368 | 0.76 | PGR (0.39) | PGRBRD4BRD2CREBBPCHEK1 | |
| SCHEMBL4165485 | 0.75 | PGR (0.67) | PGRCHEK1NR3C1ARNR3C2 | |
| SCHEMBL12577690 | 0.68 | BRD4 (0.59) | PGRBRD4BRD2CREBBPCHEK1 | |
| SCHEMBL2689671 | 0.68 | BRD4 (0.52) | PGRBRD4BRD2CREBBPCHEK1 | |
| SCHEMBL5500966 | 0.68 | BRD4 (0.49) | PGRBRD4BRD2CREBBPMAPT | |
| SCHEMBL5500199 | 0.66 | ALDH1A1 (0.60) | BRD4BRD2CREBBPLMNATP53 | |
| SCHEMBL5498807 | 0.65 | PGR (0.37) | PGRNR3C1ARNR3C2MAPT | |
| SCHEMBL16426263 | 0.64 | BRD4 (0.55) | PGRBRD4BRD2CREBBP | |
| SCHEMBL10389918 | 0.64 | MAP4K4 (0.59) | PGRBRD4BRD2CREBBPCHEK1 | |
| SCHEMBL4212927 | 0.64 | RXRA (0.71) | PGRBRD4BRD2CREBBPCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | claimed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | PGR 953/4885BRD4 933/4885BRD2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.